CK Life Sciences (00775) has released its interim results for 2026, reporting revenue of HK$2.716 billion, up 4.22% year-on-year. The company recorded a loss attributable to shareholders of HK$28.73 million, a significant reduction of 80.95% compared to the same period last year. Loss per share stood at 0.3 HK cents.

In the second half of 2025, the company undertook a corporate restructuring aimed at strengthening its research and development capabilities. This initiative involved bringing in more specialized talent and advanced technologies to enhance execution efficiency. The restructuring included the acquisition of CK Life Sciences' research-focused subsidiary, Polynoma, by TransCode Therapeutics (RNAZ), a company listed on the Nasdaq in the United States.

Under the terms of the transaction, CK Life Sciences is expected to become a major shareholder of RNAZ. During the first half of 2026, because RNAZ shareholders had not yet approved the change in control, the relevant expenses for both Polynoma and RNAZ were not included in the company's consolidated financial statements. This change in accounting treatment led to a significant reduction in research and development expenses for the reporting period, consequently resulting in a smaller loss compared to the prior year.